Tomohiro Koga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8175558/publications.pdf Version: 2024-02-01



Томониро Косл

#	Article	IF	CITATIONS
1	The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology, 2012, 51, 1278-1284.	1.9	252
2	CaMK4-dependent activation of AKT/mTOR and CREM- $\hat{l}\pm$ underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	8.2	185
3	IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4â^'CD8â^' IL-17–Producing T Cells. Journal of Immunology, 2014, 193, 2168-2177.	0.8	105
4	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. Journal of Immunology, 2012, 189, 3490-3496.	0.8	91
5	T cells and IL-17 in lupus nephritis. Clinical Immunology, 2017, 185, 95-99.	3.2	89
6	Cutting Edge: Calcium/Calmodulin-Dependent Protein Kinase Type IV Is Essential for Mesangial Cell Proliferation and Lupus Nephritis. Journal of Immunology, 2011, 187, 5500-5504.	0.8	66
7	cAMP Responsive Element Modulator (CREM) α Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â~'CD8â~' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	3.4	66
8	ICER is requisite for Th17 differentiation. Nature Communications, 2016, 7, 12993.	12.8	64
9	Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Research and Therapy, 2016, 18, 175.	3.5	63
10	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3 ⁺ regulatory T cells in MRL/ <i>lpr</i> mice. Autoimmunity, 2014, 47, 445-450.	2.6	60
11	cAMP-responsive Element Modulator α (CREMα) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â°'CD8â°' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	3.4	53
12	Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. Journal of Immunology, 2015, 195, 5533-5537.	0.8	53
13	Serum amyloid Aâ€induced ILâ€6 production by rheumatoid synoviocytes. FEBS Letters, 2008, 582, 579-585.	2.8	51
14	Lupus Nephritis IgG Induction of Calcium/Calmodulinâ€Dependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function. Arthritis and Rheumatology, 2016, 68, 944-952.	5.6	50
15	Multiple Serum Cytokine Profiling to Identify Combinational Diagnostic Biomarkers in Attacks of Familial Mediterranean Fever. Medicine (United States), 2016, 95, e3449.	1.0	48
16	The Role of Interleukin-6 in Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, 23-36.	2.2	43
17	Tofacitinib inhibits granulocyte–macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Research and Therapy, 2018, 20, 196.	3.5	43
18	Calcium/Calmodulinâ€Dependent Kinase IV Facilitates the Recruitment of Interleukinâ€17–Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cell–Driven Inflammatory Diseases. Arthritis and Rheumatology, 2016, 68, 1981-1988.	5.6	41

#	Article	IF	CITATIONS
19	Promotion of Calcium/Calmodulinâ€Dependent Protein Kinase 4 by GLUT1â€Dependent Glycolysis in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 766-772.	5.6	41
20	The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Review of Clinical Immunology, 2019, 15, 629-637.	3.0	39
21	Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. Modern Rheumatology, 2018, 28, 161-167.	1.8	36
22	Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium. Journal of Rheumatology, 2011, 38, 2309-2317.	2.0	35
23	Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (United States), 2016, 95, e4871.	1.0	34
24	Familial Mediterranean fever: overview of pathogenesis, clinical features and management. Immunological Medicine, 2018, 41, 55-61.	2.6	33
25	Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Medicine (United States), 2019, 98, e15578.	1.0	33
26	MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway. Rheumatology, 2018, 57, 718-726.	1.9	30
27	ILâ€15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. Journal of Internal Medicine, 2021, 289, 206-220.	6.0	30
28	Biologic therapy in familial Mediterranean fever. Modern Rheumatology, 2016, 26, 637-641.	1.8	28
29	Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 624971.	4.8	26
30	Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease. Arthritis Research and Therapy, 2017, 19, 199.	3.5	25
31	The role of CaMK4 in immune responses. Modern Rheumatology, 2018, 28, 211-214.	1.8	24
32	Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS ONE, 2017, 12, e0175281.	2.5	24
33	Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology, 2009, 48, 741-747.	1.9	23
34	Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation. Clinical Immunology, 2016, 173, 147-148.	3.2	23
35	Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus. Clinical Immunology, 2018, 193, 123-130.	3.2	23
36	Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clinical Immunology, 2021, 225, 108680.	3.2	23

#	Article	IF	CITATIONS
37	Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern Rheumatology, 2013, 23, 190-194.	1.8	21
38	Ultrasonographic Efficacy of Biologic and Targeted Synthetic Diseaseâ€Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan. Arthritis Care and Research, 2018, 70, 1719-1726.	3.4	21
39	Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis. Arthritis Research and Therapy, 2020, 22, 108.	3.5	20
40	Anti-MDA5 Antibody-positive Dermatomyositis Complicated by Autoimmune-associated Hemophagocytic Syndrome That Was Successfully Treated with Immunosuppressive Therapy and Plasmapheresis. Internal Medicine, 2018, 57, 3473-3478.	0.7	19
41	Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan. Arthritis Research and Therapy, 2018, 20, 257.	3.5	18
42	Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren's syndrome complicated with IgM monoclonal gammopathy of undetermined significance. Rheumatology International, 2013, 33, 227-230.	3.0	16
43	Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 2219-2220.	0.9	16
44	Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease. Medicine (United States), 2018, 97, e13394.	1.0	16
45	Effect of a gonadotropinâ€releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. International Journal of Rheumatic Diseases, 2018, 21, 1287-1292.	1.9	16
46	Generation and characterization of antagonistic anti-human interleukin (IL)-18 monoclonal antibodies with high affinity: Two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18. Archives of Biochemistry and Biophysics, 2019, 663, 71-82.	3.0	16
47	Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan. BMC Musculoskeletal Disorders, 2021, 22, 506.	1.9	16
48	Magnetic Resonance Imaging Bone Edema at Enrollment Predicts Rapid Radiographic Progression in Patients with Early RA: Results from the Nagasaki University Early Arthritis Cohort. Journal of Rheumatology, 2016, 43, 1278-1284.	2.0	14
49	A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. Modern Rheumatology, 2019, 29, 302-305.	1.8	14
50	Post-transcriptional regulation of IL-6 production by Zc3h12a in fibroblast-like synovial cells. Clinical and Experimental Rheumatology, 2011, 29, 906-12.	0.8	14
51	Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice. Medicine (United States), 2016, 95, e3476.	1.0	13
52	Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. Medicine (United States), 2018, 97, e13450.	1.0	13
53	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 94-102.	0.9	13
54	Galectin-9 in autoimmune hepatitis. Medicine (United States), 2019, 98, e16924.	1.0	11

#	Article	IF	CITATIONS
55	Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clinical Immunology, 2020, 215, 108451.	3.2	11
56	Podocyte foot process width is a prediction marker for complete renal response at 6 and 12â€ ⁻ months after induction therapy in lupus nephritis. Clinical Immunology, 2018, 197, 161-168.	3.2	10
57	Serial analysis of cytokine and chemokine profiles and viral load in severe fever with thrombocytopenia syndrome. Medicine (United States), 2019, 98, e17571.	1.0	10
58	Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. Scandinavian Journal of Rheumatology, 2020, 49, 13-17.	1.1	10
59	An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance. Medicine (United States), 2020, 99, e18328.	1.0	10
60	CD4+ CD52lo T-cell expression contributes to the development of systemic lupus erythematosus. Clinical Immunology, 2018, 187, 50-57.	3.2	9
61	Antineutrophilic cytoplasmic antibodyâ€associated vasculitis with and without renal involvement: C3 contributes to prognosis, but renal involvement does not. International Journal of Rheumatic Diseases, 2019, 22, 789-796.	1.9	9
62	Differences in musculoskeletal ultrasound findings between RS3PE syndrome and elderly-onset rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 1981-1988.	2.2	9
63	Methotrexate Alters the Expression of microRNA in Fibroblast-like Synovial Cells in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 11561.	4.1	9
64	Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. Trials, 2018, 19, 715.	1.6	8
65	Juvenile onset autoinflammatory disease due to a novel mutation in TNFAIP3 (A20). Arthritis Research and Therapy, 2018, 20, 274.	3.5	8
66	ldiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene. Rheumatology, 2021, 60, 445-450.	1.9	8
67	Candidate biomarkers for idiopathic multicentric Castleman disease. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, 62, 85-90.	0.8	8
68	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. Internal Medicine, 2018, 57, 2247-2250.	0.7	7
69	Combination of ultrasound power Dopplerâ€verified synovitis and seropositivity accurately identifies patients with earlyâ€stage rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 842-851.	1.9	7
70	Mediterranean fever gene variants modify clinical phenotypes of idiopathic multiâ€centric Castleman disease. Clinical and Experimental Immunology, 2021, 206, 91-98.	2.6	7
71	A case of primary Sjögren's syndrome complicated with inflammatory myopathy and interstitial lung disease. Rheumatology International, 2012, 32, 3647-3649.	3.0	6
72	Synovitis of sternoclavicular and peripheral joints can be detected by ultrasound in patients with SAPHO syndrome. Modern Rheumatology, 2017, 27, 881-885.	1.8	6

#	Article	IF	CITATIONS
73	Diagnosis and treatment of autoinflammatory diseases in adults: a clinical approach from rheumatologists. Immunological Medicine, 2018, 41, 177-180.	2.6	6
74	Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. Immunological Medicine, 2018, 41, 181-186.	2.6	6
75	HLA-DQB1 DPB1 alleles in Japanese patients with adult-onset Still's disease. Modern Rheumatology, 2019, 29, 843-847.	1.8	6
76	Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease. Medicine (United States), 2019, 98, e15237.	1.0	6
77	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease. Medicine (United States), 2020, 99, e20710.	1.0	6
78	Fluorescence optical imaging in patients with active rheumatoid arthritis: a comparison with ultrasound and an association with biomarkers. Scandinavian Journal of Rheumatology, 2021, 50, 95-103.	1.1	6
79	Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population. Clinical and Experimental Rheumatology, 2011, 29, 811-5.	0.8	6
80	Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy. Clinical Immunology, 2016, 165, 35-37.	3.2	5
81	Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus. Rheumatology, 2020, 59, 903-905.	1.9	5
82	Successful canakinumab treatment for activated innate response in idiopathic Castleman's disease with multiple heterozygous MEFV exon 2 variants. Clinical Immunology, 2020, 219, 108547.	3.2	5
83	Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis. Rheumatology, 2023, 62, 861-871.	1.9	5
84	Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 2018, 47, 331-333.	1.1	4
85	Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA). Medicine (United States), 2021, 100, e26592.	1.0	4
86	Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study. Modern Rheumatology, 2022, 32, 797-802.	1.8	4
87	Sweet's Syndrome Complicated by Kikuchi's Disease and Hemophagocytic Syndrome which Presented with Retinoic Acid-inducible Gene-I in both the Skin Epidermal Basal Layer and the Cervical Lymph Nodes. Internal Medicine, 2013, 52, 1839-1843.	0.7	3
88	Subclinical inflammation in a case of menstruation-induced familial Mediterranean fever. Medicine (United States), 2018, 97, e12305.	1.0	3
89	Atypical Familial Mediterranean Fever Complicated with Gastrointestinal Amyloidosis Diagnosed due to Paroxysmal Arthralgia and Intractable Diarrhea, Successfully Treated with Tocilizumab. Internal Medicine, 2019, 58, 1781-1785.	0.7	3
90	Novel multiple heterozygous NUDT15 variants cause an azathioprine-induced severe leukopenia in a patient with systemic lupus erythematosus. Clinical Immunology, 2019, 200, 64-65.	3.2	3

#	Article	IF	CITATIONS
91	Paediatric-onset haploinsufficiency of A20 associated with a novel and de novo nonsense TNFAIP3 mutation. Rheumatology, 2020, 59, e85-e87.	1.9	3
92	Genetic and clinical characteristics associated with efficacy and retention rates of colchicine in Japanese patients with familial Mediterranean fever: A single-center observational study. Modern Rheumatology, 2021, 31, 762-763.	1.8	3
93	Contributing factors of clinical outcomes at 1 year post-diagnosis in early rheumatoid arthritis patients with tightly controlled disease activity in clinical practice: a retrospective study. Modern Rheumatology, 2021, 31, 343-349.	1.8	3
94	Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation. Clinical Immunology, 2021, 227, 108732.	3.2	3
95	A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus. Clinical Immunology, 2021, 233, 108887.	3.2	3
96	Successful treatment of sepsis-induced disseminated intravascular coagulation in a patient with idiopathic thrombocytopenic purpura using recombinant human soluble thrombomodulin. Rheumatology International, 2011, 31, 1657-1659.	3.0	2
97	Coexistence of Mixed Connective Tissue Disease and Familial Mediterranean Fever in a Japanese Patient. Internal Medicine, 2019, 58, 2235-2240.	0.7	2
98	A case of neutrophilic dermatosis with <i>MEFV</i> gene variant and abnormal activation of peripheral blood monocytes: a case report. Immunological Medicine, 2019, 42, 45-49.	2.6	2
99	Comparison of complications during 1-year follow-up between remitting seronegative symmetrical synovitis with pitting edema syndrome and elderly-onset rheumatoid arthritis. Immunological Medicine, 2022, , 1-7.	2.6	2
100	Generation of antagonistic monoclonal antibodies against the neoepitope of active mouse interleukin (IL)-18 cleaved by inflammatory caspases. Archives of Biochemistry and Biophysics, 2022, 727, 109322.	3.0	2
101	Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) â ^{-,} 77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis. Modern Rheumatology, 2011, 21, 240-243.	1.8	1
102	Familial Mediterranean fever complicated with refractory asthma: Successful treatment with colchicine. Modern Rheumatology, 2017, 27, 182-183.	1.8	1
103	Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis. Clinical Immunology, 2018, 197, 107-109.	3.2	1
104	A case of familial Mediterranean fever triggered by acute adrenal insufficiency due to an abrupt withdrawal of corticosteroids. Modern Rheumatology Case Reports, 2018, 2, 221-224.	0.7	1
105	Cutaneous polyarteritis nodosa with necrotising vasculitis in the fascia. Modern Rheumatology Case Reports, 2018, 2, 195-198.	0.7	1
106	The potential role of CD4+CD52lo T-cell populations in systemic lupus erythematosus. Clinical Immunology, 2019, 200, 35-36.	3.2	1
107	Reduction in the percentage of circulating variable delta 2ÂT cells in systemic lupus erythematosus. Clinical Immunology, 2020, 220, 108577.	3.2	1
108	Large deletion in 6q containing the TNFAIP3 gene associated with autoimmune lymphoproliferative syndrome. Clinical Immunology, 2022, 235, 108853.	3.2	1

#	Article	IF	CITATIONS
109	Tissue resident cell processes determine organ damage in systemic lupus erythematosus. Clinical Immunology, 2022, 234, 108919.	3.2	1
110	Atypical phenotype without fever in a Japanese family with an autosomal dominant transmission of familial Mediterranean fever due to heterozygous MEFV Thr577Asn mutations. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 161-162.	0.8	1
111	The possession of exon 2 or exon 3 variants in the MEFV gene promotes inflammasome activation in Japanese patients with familial Mediterranean fever with a heterozygous exon 10 mutation. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 49-52.	0.8	1
112	THU0057â€Kn-93, an Inhibitor of Calcium/Calmodulin-Dependent Protein Kinase Iv, Promotes Generation and Function of Foxp3+ Regulatory T Cells in Mrl/Lpr Mice. Annals of the Rheumatic Diseases, 2014, 73, 195.3-196.	0.9	0
113	FRI0018â€CAMK4 Inhibition Prevents Recruitment of IL-17 Producing Cells to Target Organs Through CCR6/CCL20 Axis in TH17 Driven Inflammatory Diseases. Annals of the Rheumatic Diseases, 2015, 74, 425.1-425.	0.9	0
114	SAT0088â€Prognostic Factors Toward Rapid Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving Treat to Target Strategy. Annals of the Rheumatic Diseases, 2015, 74, 680.2-680.	0.9	0
115	AB0180â€The Role of Immune Regulation of CD4+CD52High T Cells in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 951.1-951.	0.9	0
116	SAT0533â€Early Diagnosis is Associated with the Less Flair in Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome. Annals of the Rheumatic Diseases, 2015, 74, 853.1-853.	0.9	0
117	A case of TAFRO syndrome successfully treated with cyclosporin A and tocilizumab. Modern Rheumatology Case Reports, 2018, 2, 209-213.	0.7	0
118	AB0172â€EXPRESSION OF SLAMF6 AND ITS FUNCTIONAL SIGNIFICANCE IN PODOCYTES OF LUPUS NEPHRITIS. 2019, , .	• •	0
119	Comment on: Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus: reply. Rheumatology, 2020, 59, e156-e157.	1.9	0
120	Successful Strategies to Recruit Patients with Familial Mediterranean Fever for a Multicenter Clinical Trial. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 3-7.	0.1	0
121	Granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α in combination is a useful diagnostic biomarker to distinguish familial Mediterranean fever from sepsis. Arthritis Research and Therapy, 2021, 23, 260.	3.5	0
122	FRI0027â€MRI-Proven Bone Marrow Oedema at Baseline is the Strongest Predictor Toward the Development of Rapid Radiographic Progression at 1 Year in Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort. Annals of the Rheumatic Diseases, 2015, 74, 428.1-428.	0.9	0
123	SAT0589â€Musculoskeletal manifestations occur predominantly in patients with older onset familial mediterranean fever. , 2018, , .		0
124	9. Familial Mediterranean Fever - Diagnosis and Clinical Management The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1918-1925.	0.0	0
125	Lung consolidation and mediastinal lymphadenopathy in patients with early anti-citrullinated protein antibody-positive rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 517-518.	0.8	0
126	Late-onset protracted febrile myalgia syndrome successfully treated with colchicine owing to heterozygous MEFV exon 2 variants. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 166.	0.8	0

#	Article	IF	CITATIONS
127	Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan. Clinical and Experimental Rheumatology, 2020, 38, 1096-1101.	0.8	0
128	Next-generation sequencing of the whole MEFV gene in Japanese patients with familial Mediterranean fever: a case-control association study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 35-41.	0.8	0